Indian Pharmaceuticals Become Suit Filers Rather Than Those Being Sued (India)
This article was originally published in PharmAsia News
Executive Summary
Now that Indian generic pharmaceutical companies are developing and marketing their own drugs, their patent role is beginning to switch from being sued to filing the suits. About 40 percent of the 8,000 drug patents filed in India between 1995 and 2004 were by Indian drug makers. A university professor says many of those patent applications are considered frivolous, claiming new laboratory techniques even though they do not qualify for patents. But he noted the pipeline of discovery drugs is drying up while companies seek another patent for a drug after changing its makeup a bit. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.